Doravirine: First Global Approval
- 435 Downloads
Doravirine is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) developed by Merck & Co for the treatment of HIV-1 infection. The drug is approved in the USA both as a single-agent tablet (Pifeltro™) and as a fixed-dose combination tablet with the nucleos(t)ide reverse transcriptase inhibitors lamivudine and tenofovir disoproxil fumarate (Delstrigo™). Each formulation is indicated in the USA for treating HIV-1 infection in adults with no prior antiretroviral treatment, has received a positive opinion in the EU for treating HIV-1 infection in adults without resistance to NNRTIs or (in the case of the fixed-dose combination tablet) lamivudine or tenofovir, and is also under regulatory review for the treatment of HIV-1 infection in Canada. This article summarizes the milestones in the development of doravirine leading to this first approval for the treatment of HIV-1 infection in treatment-naïve adults.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Emma Deeks is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 1.Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2018. https://aidsinfo.nih.gov/guidelines. Accessed 19 Sept 2018.
- 2.British HIV Association. BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy. 2015 (2016 interim update). http://www.bhiva.org/. Accessed 18 Sept 2018.
- 3.European AIDS Clinical Society. Guidelines version 9.0. 2017. http://eacsociety.org/. Accessed 18 Sept 2018.
- 5.Duarte CA, Paneque T, Ramirez AC, et al. From AZT to treatment as prevention. The evolution of antiretroviral therapy for HIV/AIDS. Biotechnol Appl. 2015;32:2101–10.Google Scholar
- 6.Merck. Pifeltro™ (doravirine) tablets, for oral use: US prescribing information. 2018. https://www.merck.com/product/usa/pi_circulars/p/pifeltro/pifeltro_pi.pdf. Accessed 19 Sept 2018.
- 7.Merck. Delstrigo™ (doravirine, lamivudine, and tenofovir disoproxil fumarate) tablets, for oral use: US prescribing information. 2018. https://www.merck.com/product/usa/pi_circulars/d/delstrigo/delstrigo_pi.pdf. Accessed 19 Sept 2018.
- 8.Merck. FDA approves Merck’s Delstrigo™ (doravirine/lamivudine/tenofovir disoproxil fumarate), a once-daily fixed-dose combination tablet as a complete regimen and Pifeltro™ (doravirine), an NNRTI, both for the treatment of HIV-1 in appropriate patients [media release]. 30 Aug 2018. https://www.mrknewsroom.com.
- 9.European Medicines Agency. Summary of opinion (initial authorisation): Pifeltro. Doravirine. 2018. https://www.ema.europa.eu/documents/smop-initial/chmp-summary-positive-opinion-pifeltro_en.pdf. Accessed 28 Sept 2018.
- 10.European Medicines Agency. Summary of opinion (initial authorisation): Delstrigo. Doravirine/lamivudine/tenofovir disoproxil. 2018. https://www.ema.europa.eu/documents/smop-initial/chmp-summary-positive-opinion-delstrigo_en.pdf. Accessed 18 Sept 2018.
- 14.Lai MT, Xu M, Ngo W, et al. Characterization of doravirine-selected resistance patterns from participants in treatment-naïve phase 3 clinical trials [conference report]. In: 22nd International AIDS conference. 2018.Google Scholar
- 15.Orkin C, Squires KE, Molina JM, et al. Doravirine/lamivudine/tenofovir disoproxil fumarate is non-inferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial. Clin Infect Dis. 2018. https://doi.org/10.1093/cid/ciy540.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Hazuda DJ, Xu M, Ngo W, et al. Understanding the resistance profile of the HIV-1 NNRTI doravirine in combination with the novel NRTTI MK-8591 [conference report]. In: 22nd International AIDS conference. 2018.Google Scholar
- 28.Molina JM, Squires K, Sax P, et al. Doravirine (DOR) versus ritonavir-boosted darunavir (DRV + r): 96-week results of the randomized, double-blind, phase 3 DRIVE-FORWARD noninferiority trial [abstract no. LBPEB017 and presentation]. In: 22nd International AIDS conference. 2018.Google Scholar
- 29.Orkin C, Squires K, Molina JM, et al. Doravirine/lamivudine/tenofovir DF continues to be non-inferior to efavirenz/emtricitabine/tenofovir DF in treatment-naïve adults with HIV-1 infection: week 96 results of the DRIVE-AHEAD trial [abstract no. LB1]. In: IDweek. 2018.Google Scholar
- 31.Kumar P, Johnson M, Molina J-M, et al. Switch to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains virologic suppression through 48 weeks: results of the DRIVE-SHIFT trial [abstract no. LB2]. In: IDWeek. 2018.Google Scholar
- 32.Gatell JM, Raffi F, Plettenberg A, et al. Doravirine 100 mg QD vs efavirenz + TDF/FTC in ART-naive HIV+ patients: week 48 results [abstract no 470]. Top HIV Med. 2016;24(e-1):183.Google Scholar